OpenNashPodcasts

Person

Matthew Pech

5 episodes · 62 quoted claims

A single roughly 10-liter botulinum toxin production run made at the University of Wisconsin in November 1979 supplied the entire US commercial Botox market from 1990 to 1997.

“It ends up supplying the entire American commercial market for Botox from 1990 to 1997.”

Approved · 0:19:11

Alan Scott took out a $400,000 mortgage on his house to buy equipment and founded Oculinum Inc. to make and develop the toxin.

“He literally takes out a $400 ,000 mortgage on his house to start buying the equipment.”

Approved · 0:43:35

The FDA approved Oculinum's botulinum toxin for strabismus on December 29, 1989, through the orphan drug pathway.

“On December 29th, 1989, through an orphan drug approval pathway, Oculinum gets official FDA approval to manufacture and sell botulinum toxin for the treatment of strabismus.”

Approved · 1:16:18

Accounts of Allergan's price for Oculinum conflict: the press and Gavin Herbert said $9 or $10 million, a later Allergan CEO said $28 million, and Alan Scott said $4.5 million.

“A later CEO of Allergan swears it's $28 million. Alan Scott says he sold it for $4.5 million.”

Approved · 1:20:49

Botox Cosmetic received FDA approval in 2002, years after dermatologists began using Botox off-label for wrinkles.

“you may be surprised to learn that Botox Cosmetic doesn't actually get FDA approval until 2002.”

Approved · 1:44:10

Allergan won FDA approval for the eyelash-growth product Latisse in December 2008, after clinicians noticed longer eyelashes as a side effect of a glaucoma drop.

“and boom, boom, boom, in December 2008, they had approval for Latisse.”

Approved · 1:55:27

Valeant Pharmaceuticals launched an unsolicited hostile takeover bid for Allergan in April 2014.

“In April 2014, a company called Valeant Pharmaceuticals launches an unsolicited, hostile takeover attempt of Allergan”

Approved · 2:04:49

Revance's Daxxify, approved in 2022, uses a peptide stabilizer that makes the toxin last about six months instead of three to four.

“The duration pressure comes from Revent's Daxify, approved in 2022. It uses a peptide stabilizer that makes the toxin last roughly six months instead of three to four.”

Approved · 3:00:48

Justinus Kerner, a German district health officer, investigated fatal sausage poisonings and tested the toxic extract on animals and himself.

“He feeds tainted sausage extract to different animals and finally puts a few drops on his own tongue.”

Approved · 0:06:42

Alan Scott published his botulinum toxin injection method in 1973 without filing a patent, which made the publication prior art that undermined later patent protection for the medical use.

“Scott publishes in 1973 the exact method he designed from scratch, the novel injection equipment, the technique, everything”

Approved · 0:29:53

Federal judge William Bryson invalidated the Restasis patents and wrote that sovereign immunity should not be a purchasable commodity for private entities.

“Sovereign immunity should not be treated as a monetizable commodity that can be purchased by private entities as part of a scheme to evade their legal responsibilities.”

Approved · 2:37:23

AbbVie agreed in June 2019 to buy Allergan for $63 billion, a 45% premium to its prior stock price.

“In June of 2019, AbbVie agrees to buy Allergan for $63 billion, representing a 45 % premium over where the stock was trading before.”

Approved · 2:51:23

Third Rock Ventures closed its first fund, of $378 million, in roughly ten weeks.

“They managed to close a fund of $378 million in something like 10 weeks, which is massively impressive.”

Approved · 0:04:37

Third Rock Ventures owned about 76% of Blueprint Medicines after its first financing round, according to the hosts' data.

“our data indicates that Third Rock owned 76 % of the company in the first round.”

Approved · 0:10:41

Gleevec also inhibits KIT, whose abnormal activation drives gastrointestinal stromal tumors (GIST).

“Aberrant kit activation drives a rare type of stomach cancer called GIST.”

Approved · 0:20:04

The idea for Blueprint Medicines began as a sketch in Alexis Borisy's notebook in October 2009.

“The idea of Blueprint Medicine starts as a sketch in Alexis Borisy's notebook in October 2009 while he's running another company.”

Approved · 0:23:34

Blueprint's Series A was about $40 million, of which $30 million came from the investor now called F-Prime.

“Blueprint Series A was about $40 million. $30 million was put in by what's now F prime.”

Approved · 0:32:39

Blueprint Medicines went public in April 2015 at $18 a share, raising about $150 million before dosing any patient.

“In April 2015, with the platform humming and the development candidate nominated for the kit program, Blueprint goes public at 18 bucks a share, raising about $150 million”

Approved · 0:42:30

The FDA approved avapritinib (Ayvakit) on January 9, 2020, for a PDGFR-alpha-driven form of GIST.

“January 9th, 2020, FDA approves avapritinib, brand name Avakit, for a specific form of GI stromal tumors.”

Approved · 1:02:02

The phase three Voyager trial of avapritinib in a broader GIST population failed on April 28, 2020.

“That spring, though, things start to turn on blueprint. On April 28th, a phase three trial called Voyager, which was testing avapritinib”

Approved · 1:02:56

Eli Lilly's RET inhibitor selpercatinib launched in May 2020, about four months before Blueprint's competing drug.

“Lilly had a competing RET drug called selpercatinib, which launched in May 2020.”

Approved · 1:09:29

By 2022 Lilly's RET drug earned about $200 million a year while Blueprint's earned under $30 million.

“By 2022, Lilly's drug is pulling in roughly $200 million a year, while Blueprint is barely doing under $30.”

Approved · 1:10:33

Blueprint's stock fell 23% on the day of the May 2023 Ayvakit approval for indolent systemic mastocytosis.

“So, an FDA approval. You might think Wall Street absolutely loved that headline, right? Nope. Stock drops 23 % the exact same day.”

Approved · 1:25:04

Ayvakit generated about half a billion dollars in sales in 2024, up 135% year over year.

“AvaKit does a half $1 billion in sales in 2024, already up 135 % year over year.”

Approved · 1:30:06

Sanofi sent Blueprint a written proposal of $124 per share in cash, about $8.5 billion, on January 17, 2025.

“four days later, on January 17th, Sanofi sends a formal written proposal. $124 a share, all cash. That's about $8.5 billion.”

Approved · 1:45:31

Gleevec co-inventor Nick Lydon received about $11 million from the Sanofi acquisition of Blueprint.

“He walks away with about $11 million. So about one-sixth of what the hired operators make.”

Approved · 2:02:53

Third Rock invested about $42 million early in Blueprint and, by the hosts' estimate, realized about $340 million.

“As a reminder, Third Rock put in roughly $42 million early on. By our estimates, they realized about $340 million on Blueprint.”

Approved · 2:05:04

Curie Bio launched in 2023 and has seeded almost 40 companies, none yet with an approved drug.

“Curie launched in 2023, and in that short window, it's already seeded almost 40 companies.”

Approved · 2:13:50

The FDA approved Yervoy (ipilimumab) in March 2011 as the first cancer drug that worked purely by releasing the immune system's brake.

“Yervoy was approved in March 2011. It was a landmark.”

Approved · 0:11:11

In 1997 Lieping Chen's team found that many cancer tissues overexpressed PD-L1 while normal tissues barely expressed it.

“in 1997, they discovered that a ton of cancer tissues overexpressed PD-L1, while normal, healthy tissues barely seemed to express it at all.”

Approved · 0:14:59

Merck and Schering-Plough agreed to a $41 billion merger in 2009, structured as a reverse merger with Schering-Plough as the legal acquirer.

“It's 2009. Merck and Shering Plough agree to a massive $41 billion mega merger.”

Approved · 0:31:21

Merck began Keynote 001, a 30-patient phase one pembrolizumab study in melanoma, in 2011.

“In 2011, they initiated a small 30-patient phase one study focused on melanoma. They call it Keynote 001.”

Approved · 0:45:05

Under Roger Perlmutter, more than half of Merck's drug development budget was redirected to pembrolizumab, funding over 700 clinical trials.

“ultimately more than half of Merck's entire drug development budget gets redirected towards pembrolizumab, ultimately fueling over 700 clinical trials across dozens of cancer types.”

Approved · 0:51:09

Merck received FDA Breakthrough Therapy Designation for pembrolizumab in January 2013, which BMS's nivolumab did not have.

“Because of that early melanoma data with Pembrolizumab, Merck applied for and got the breakthrough designation in January 2013, a few months before Perimuter arrived on site.”

Approved · 0:55:58

A 41-patient Johns Hopkins trial tested Keytruda in patients with and without DNA repair-deficient tumors, finding response rates of 40 to 71% in the deficient group.

“set up their own small 41-patient trial to test Keytruda in both patients who had DNA repair-deficient tumors and in patients with normal tumors.”

Approved · 1:14:43

In 2018 Merck published Keynote 189, which combined Keytruda with chemotherapy in lung cancer patients regardless of PD-L1 status.

“In 2018, Merck publishes the results of their combination trial, Keynote 189. They gave Keytruda and standard of care chemotherapy to all comers”

Approved · 1:18:24

In the Keynote 6 melanoma trial, 34% of Keytruda patients were alive after 10 years of follow-up.

“In Keynote 6, 34 % of Keytruda patients are alive after 10-year follow-up.”

Approved · 1:35:42

MRC Technology, which helped humanize pembrolizumab, sold part of its royalty rights to a private equity fund for about $150 million before Keytruda's sales took off.

“they decided to sell a chunk of their royalty rights off to a private equity fund for about $150 million.”

Approved · 1:42:17

Former U.S. president Jimmy Carter disclosed in August 2015, at age 90, that he had metastatic melanoma that had spread to his brain, and was treated with radiation and pembrolizumab.

“In August 2015, former president Jimmy Carter disclosed that he had metastatic melanoma that had spread to his brain. He was 90 years old at the time.”

Approved · 2:05:52

In 1912 Alexis Carrel, a surgeon at the Rockefeller Institute, claimed he could keep chicken heart cells alive in culture indefinitely, a belief that shaped the dogma Hayflick challenged.

“In 1912, Alexis Carell, a French surgeon at the Rockefeller Institute, a Nobel laureate and a eugenicist, claimed he could keep chicken heart cells alive in culture indefinitely.”

Approved · 0:02:49